Retatrutide – Rex Pharmaceuticals 24/7

Retatrutide is a novel, investigational peptide-based medication being developed by Eli Lilly and Company. It is currently in Phase 3 clinical trials and is not yet approved for public use by any regulatory agency like the FDA or EMA.